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Background: Glycoprotein 2b/3a Inhibitors (GPI) reduce ischemic complications following percutaneous coronary intervention (PCI). However, 
there have been significant advances in PCI since their introduction, with sparse data on contemporary safety outcomes.
methods: We analyzed the CathPCI Registry® to assess GPI use and PCI outcomes in acute coronary syndromes (ACS) from 7/2009 to 9/2011. 
Our primary outcome was all-cause in-hospital mortality. The secondary outcome was major bleeding. To adjust for potential selection bias, we used 
multivariable regression, propensity matching, and instrumental variable analyses (in which we compared high use hospitals [>70% GPI use] vs. low 
use hospitals [<10% GPI use]). Both relative risks and absolute risk differences are included to allow standardization of reporting.
results: During the study period there were 1,465,498 PCIs recorded. After excluding patients undergoing elective PCI (n=407,942) or PCI at 
hospitals performing <50 PCI/year (n= 86,691), the study cohort was 970,865 PCI. Of these, GPI were used in 33.6%. Results are presented in the 
Table.
conclusion: Among unselected ACS patients undergoing contemporary PCI, GPI use was associated with a reduced risk of in-hospital mortality that 
was confirmed across multiple risk-adjustment Methods.  This benefit comes at a cost of more frequent post-PCI bleeding. These findings suggest 
that in the modern era of PCI there is still a role for the judicious use of GPI in selected patients.
Outcome Analytic Method
Absolute Risk Difference 
(%)*
95% Confidence 
Interval
Relative Risk
95% Confidence 
Interval
p-value
Death Unadjusted 1.02 (0.96,1.08) 1.76 (1.70, 1.81) <0.001
Multivariable -0.25 (-0.49, -0.02) 0.83 (0.79, 0.88) <0.001
Propensity Matched -0.22 (-0.33, -0.11) 0.90 (0.86, 0.95) <0.001
Instrumental Variable -0.39 (-0.70, -0.04) 0.72 (0.50, 0.97) 0.03
Major Bleeding Unadjusted 2.22 (2.16, 2.30) 2.58 (2.51, 2.65) <0.001
Multivariable 1.38 (1.2, 1.6) 1.93 1.93 (1.83, 2.04) <0.001
Propensity Matched 1.38 (1.3, 1.5) 1.83 1.83 (1.74, 1.92) <0.001
Instrumental Variable 0.80 (0.4, 1.7) 1.53 1.53 (1.27, 2.13) <0.001
